Nonalcoholic Fatty Liver Disease

Area of Science:

• Hepatology
• Internal Medicine
• Public Health

Background:

• Nonalcoholic fatty liver disease (NAFLD) is the primary driver of chronic liver disease globally.
• Diagnosis frequently occurs incidentally via elevated liver enzymes or imaging showing hepatic steatosis.
• NAFLD ranges from simple fatty liver to progressive nonalcoholic steatohepatitis (NASH) with inflammation and fibrosis.

Purpose of the Study:

• To summarize the current understanding of Nonalcoholic Fatty Liver Disease (NAFLD) diagnosis, progression, and management.
• To highlight the significant association between NAFLD and cardiovascular disease mortality.
• To emphasize the current therapeutic strategies for NAFLD.

Main Methods:

• Literature review of NAFLD prevalence, diagnosis, and clinical outcomes.
• Analysis of mortality data linking NAFLD and cardiovascular disease.
• Summary of current treatment guidelines for NAFLD.

Main Results:

• Cardiovascular disease is the leading cause of mortality in individuals with NAFLD.
• Nonalcoholic steatohepatitis (NASH) is associated with increased liver-related mortality.
• Effective pharmacologic treatments for NAFLD are currently lacking.

Conclusions:

• Lifestyle modification and weight loss are the primary therapeutic interventions for NAFLD.
• Further research is needed to develop targeted pharmacologic therapies for NAFLD and NASH.
• Early diagnosis and management of NAFLD are crucial for mitigating long-term health risks, including cardiovascular events.